======= GLMN =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: GLMN
  * **<color #00a2e8>Official Name</color>**: glomulin, FKBP associated protein
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=11146|11146]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/Q92990|Q92990]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=GLMN&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20GLMN|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/601749|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**:  This gene encodes a phosphorylated protein that is a member of a Skp1-Cullin-F-box-like complex. The protein is essential for normal development of the vasculature and mutations in this gene have been associated with glomuvenous malformations, also called glomangiomas. Multiple splice variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2016]. 
  * **<color #00a2e8>UniProt Summary</color>**:  Essential for normal development of the vasculature. May represent a naturally occurring ligand of the immunophilins FKBP59 and FKBP12. May function as an membrane anchoring protein. Isoform 1 may stimulate the p70S6K pathway. Isoform 2 may inhibit cell proliferation and increase IL2 production. {ECO:0000269|PubMed:11571281, ECO:0000269|PubMed:12604780}.

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|Kinetochor Ybp2|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|ubiquitin-protein transferase inhibitor activity|
|hepatocyte growth factor receptor binding|
|cullin-RING ubiquitin ligase complex|
|Cul4A-RING E3 ubiquitin ligase complex|
|positive regulation of interleukin-2 biosynthetic process|
|Cul2-RING ubiquitin ligase complex|
|regulation of interleukin-2 biosynthetic process|
|positive regulation of interleukin-2 production|
|Cul3-RING ubiquitin ligase complex|
|regulation of interleukin-2 production|
|negative regulation of T cell proliferation|
|positive regulation of cytokine biosynthetic process|
|vasculogenesis|
|negative regulation of protein ubiquitination|
|negative regulation of lymphocyte proliferation|
|negative regulation of mononuclear cell proliferation|
|negative regulation of leukocyte proliferation|
|negative regulation of protein modification by small protein conjugation or removal|
|neural tube closure|
|tube closure|
|primary neural tube formation|
|regulation of cytokine biosynthetic process|
|neural tube formation|
|negative regulation of T cell activation|
|negative regulation of leukocyte cell-cell adhesion|
|regulation of proteasomal ubiquitin-dependent protein catabolic process|
|embryonic epithelial tube formation|
|epithelial tube formation|
|positive regulation of cytokine secretion|
|negative regulation of lymphocyte activation|
|morphogenesis of embryonic epithelium|
|tube formation|
|regulation of ubiquitin-dependent protein catabolic process|
|regulation of T cell proliferation|
|neural tube development|
|negative regulation of leukocyte activation|
|negative regulation of cell-cell adhesion|
|regulation of proteasomal protein catabolic process|
|negative regulation of cell activation|
|regulation of protein ubiquitination|
|regulation of cytokine secretion|
|regulation of lymphocyte proliferation|
|regulation of mononuclear cell proliferation|
|regulation of proteolysis involved in cellular protein catabolic process|
|regulation of leukocyte proliferation|
|regulation of protein modification by small protein conjugation or removal|
|regulation of gene expression, epigenetic|
|muscle cell differentiation|
|regulation of cellular protein catabolic process|
|positive regulation of protein secretion|
|negative regulation of cell adhesion|
|positive regulation of peptide secretion|
|ubiquitin protein ligase binding|
|regulation of leukocyte cell-cell adhesion|
|epithelial tube morphogenesis|
|regulation of T cell activation|
|regulation of protein catabolic process|
|regulation of cell-cell adhesion|
|positive regulation of secretion by cell|
|blood vessel morphogenesis|
|positive regulation of protein transport|
|morphogenesis of an epithelium|
|positive regulation of secretion|
|negative regulation of immune system process|
|positive regulation of cytokine production|
|positive regulation of establishment of protein localization|
|regulation of protein secretion|
|muscle structure development|
|blood vessel development|
|regulation of peptide secretion|
|vasculature development|
|regulation of lymphocyte activation|
|cardiovascular system development|
|tissue morphogenesis|
|embryonic morphogenesis|
|negative regulation of protein modification process|
|regulation of leukocyte activation|
|chordate embryonic development|
|regulation of cell activation|
|embryo development ending in birth or egg hatching|
|tube morphogenesis|
|negative regulation of cell population proliferation|
|regulation of cell adhesion|
|regulation of cytokine production|
|regulation of protein transport|
|regulation of proteolysis|
|regulation of peptide transport|
|regulation of establishment of protein localization|
|regulation of secretion by cell|
|regulation of secretion|
|regulation of cellular catabolic process|
|tube development|
|circulatory system development|
|anatomical structure formation involved in morphogenesis|
|embryo development|
|positive regulation of transport|
|regulation of catabolic process|
|regulation of protein localization|
|negative regulation of cellular protein metabolic process|
|positive regulation of phosphorylation|
|negative regulation of protein metabolic process|
|epithelium development|
|positive regulation of phosphate metabolic process|
|positive regulation of phosphorus metabolic process|
|regulation of phosphorylation|
|regulation of cell population proliferation|
|regulation of immune system process|
|positive regulation of protein metabolic process|
|positive regulation of multicellular organismal process|
|tissue development|
|regulation of phosphate metabolic process|
|regulation of phosphorus metabolic process|
|regulation of protein modification process|
|regulation of transport|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of biosynthetic process|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='primary' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp21|MLN-4924 0.2μM R00 exp21]]|-2.43|
|[[:results:exp102|Nifuroxazide 5μM R03 exp102]]|-2.19|
|[[:results:exp413|THZ531 0.11 to 0.175μM on day4 R07 exp413]]|-1.88|
|[[:results:exp510|Nicotine 3000μM R08 exp510]]|-1.81|
|[[:results:exp13|Chloramphenicol 20μM R00 exp13]]|1.72|
|[[:results:exp45|Docetaxel 0.002μM R01 exp45]]|1.74|
|[[:results:exp108|Vinblastine 0.2μM R03 exp108]]|1.79|
|[[:results:exp515|PU-H71 1μM R08 exp515]]|1.8|
|[[:results:exp478|Doxorubicin 0.02μM R08 exp478]]|1.86|
|[[:results:exp217|Mdivi-1 15μM R05 exp217]]|1.86|
|[[:results:exp259|6-Thio-2-deoxyguanosine 2μM R06 exp259]]|1.91|
|[[:results:exp460|BML-284 0.09μM R08 exp460]]|2.08|
|[[:results:exp106|UM131593 0.2μM R03 exp106]]|2.24|
|[[:results:exp2|5-Fluorouracil 20μM R00 exp2]]|2.4|
|[[:results:exp360|Genistein 15μM R07 exp360]]|2.53|
|[[:results:exp3|Actinomycin-D 0.001μM R00 exp3]]|3.09|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
^Gene^Correlation^
|[[:human genes:u:ube2g1|UBE2G1]]|0.583|
|[[:human genes:f:fkbp5|FKBP5]]|0.557|
|[[:human genes:u:uba3|UBA3]]|0.501|
|[[:human genes:n:nae1|NAE1]]|0.456|
|[[:human genes:c:cbx3|CBX3]]|0.453|
|[[:human genes:t:tmem161b|TMEM161B]]|0.433|
|[[:human genes:u:ube2m|UBE2M]]|0.431|
|[[:human genes:t:thoc6|THOC6]]|0.421|
|[[:human genes:o:otud5|OTUD5]]|0.419|
|[[:human genes:u:ubr5|UBR5]]|0.413|
|[[:human genes:s:slc25a26|SLC25A26]]|0.405|
|[[:human genes:u:ube2l3|UBE2L3]]|0.404|
|[[:human genes:t:triap1|TRIAP1]]|0.401|
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 13/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|2/28|
|blood|0/28|
|bone|0/26|
|breast|1/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|1/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|4/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|1/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|1/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 2753
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 5.17 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='GLMN Expression in NALM6 Cells: 5.17'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>